DanCann Pharma A/S (NGM:DANCAN)

Market Cap	2.91M
Revenue (ttm)	5.94M
Net Income (ttm)	-14.78M
Shares Out	3.99M
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,412
Average Volume	132,387
Open	0.5050
Previous Close	0.5450
Day's Range	0.4500 - 0.5050
52-Week Range	0.1430 - 3.2000
Beta	1.93
RSI	54.02
Earnings Date	Feb 27, 2026

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK